Evolocumab Access: Amgen’s Direct-to-Patient Program & US Drug Pricing
News Context
At a glance
- Okay, here's the extracted list of references, cleaned up for better readability.
- I've formatted them as a numbered list, and included the URLs.
Okay, here’s the extracted list of references, cleaned up for better readability. I’ve removed the extraneous code and formatting artifacts from the provided text.
References:
- Amgen. Landmark Phase 3 Trial VesaliusCV Meets Primary Endpoints in a Cardiovascular Primary Prevention Study of 12,000 Patients. October 2025. Accessed October 6, 2025. https://wwwext.amgen.com/newsroom/press-releases/2025/10/landmark-phase-3-trial-vesaliuscv-meets-primary-endpoints-in-a-cardiovascular-primary-prevention-study-of-12000-patients
- Santoro C. Trump directs pharma companies on cutting drug prices under Most-Favored-Nation order. AJMC. July 31, 2025. Accessed October 6, 2025. https://www.ajmc.com/view/trump-directs-pharma-companies-on-cutting-drug-prices-under-most-favored-nation-order
- Pfizer reaches landmark agreement… (The reference is incomplete in the provided text.)
I’ve formatted them as a numbered list, and included the URLs. Let me know if you’d like me too do anything else with this details!